Dr. Sam Teichman, MD

NPI: 1679998504
Total Payments
$620,961
2020 Payments
$33,400
Companies
5
Transactions
43

Payment Breakdown by Category

Consulting$559,410 (90.1%)
Research$52,800 (8.5%)
Travel$8,608 (1.4%)
Food & Beverage$142.25 (0.0%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $559,410 34 90.1%
Unspecified $52,800 1 8.5%
Travel and Lodging $8,608 6 1.4%
Food and Beverage $142.25 2 0.0%

Payments by Type

General
$568,161
42 transactions
Research
$52,800
1 transactions

Top Paying Companies

Company Total Records Latest Year
Synergy Pharmaceuticals Inc $268,800 13 $0 (2018)
Array BioPharma Inc. $149,897 18 $0 (2019)
Retrophin, Inc. $116,064 9 $0 (2018)
Bausch Health US, LLC $52,800 1 $0 (2019)
PFIZER INC. $33,400 2 $0 (2020)

Payment History by Year

Year Amount Transactions Top Company
2020 $33,400 2 PFIZER INC. ($33,400)
2019 $202,697 19 Array BioPharma Inc. ($149,897)
2018 $317,664 20 Synergy Pharmaceuticals Inc ($201,600)
2017 $67,200 2 Synergy Pharmaceuticals Inc ($67,200)

All Payment Transactions

43 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
03/05/2020 PFIZER INC. Consulting Fee Cash or cash equivalent $24,400.00 General
03/04/2020 PFIZER INC. Consulting Fee Cash or cash equivalent $9,000.00 General
12/05/2019 Array BioPharma Inc. Consulting Fee Cash or cash equivalent $13,900.00 General
12/05/2019 Array BioPharma Inc. Travel and Lodging Cash or cash equivalent $852.62 General
12/05/2019 Array BioPharma Inc. Travel and Lodging Cash or cash equivalent $410.57 General
12/05/2019 Array BioPharma Inc. Food and Beverage In-kind items and services $35.00 General
10/31/2019 Array BioPharma Inc. Consulting Fee Cash or cash equivalent $13,500.00 General
10/10/2019 Array BioPharma Inc. Consulting Fee Cash or cash equivalent $13,500.00 General
10/10/2019 Array BioPharma Inc. Travel and Lodging Cash or cash equivalent $4,730.58 General
10/10/2019 Array BioPharma Inc. Travel and Lodging Cash or cash equivalent $2,016.37 General
10/10/2019 Array BioPharma Inc. Food and Beverage In-kind items and services $107.25 General
09/05/2019 Array BioPharma Inc. Consulting Fee Cash or cash equivalent $11,300.00 General
08/10/2019 Bausch Health US, LLC TRULANCE (Drug) Cash or cash equivalent $52,800.00 Research
Study: A Randomized, Double Blind, Placebo-controlled, Dose Ranging, Parallel-group study of the Efficacy and Safety of Plecanatide in Chinldren 6 to 18 Years of Age with Irritable Bowel Syndrome with Constipation IBS-C • Category: GASTROENTEROLOGY
08/01/2019 Array BioPharma Inc. Consulting Fee Cash or cash equivalent $6,700.00 General
07/11/2019 Array BioPharma Inc. Consulting Fee Cash or cash equivalent $9,000.00 General
05/16/2019 Array BioPharma Inc. Consulting Fee Cash or cash equivalent $19,600.00 General
04/04/2019 Array BioPharma Inc. Consulting Fee Cash or cash equivalent $12,700.00 General
03/07/2019 Array BioPharma Inc. Consulting Fee Cash or cash equivalent $14,600.00 General
01/31/2019 Array BioPharma Inc. Consulting Fee Cash or cash equivalent $17,100.00 General
01/31/2019 Array BioPharma Inc. Travel and Lodging Cash or cash equivalent $144.46 General
01/10/2019 Array BioPharma Inc. Consulting Fee Cash or cash equivalent $9,700.00 General
12/10/2018 Synergy Pharmaceuticals Inc Trulance (Drug) Consulting Fee Cash or cash equivalent $19,200.00 General
Category: Gastroenterology
12/06/2018 Retrophin, Inc. Consulting Fee Cash or cash equivalent $10,800.00 General
09/07/2018 Synergy Pharmaceuticals Inc Trulance (Drug) Consulting Fee Cash or cash equivalent $19,200.00 General
Category: Gastroenterology
09/01/2018 Retrophin, Inc. Consulting Fee Cash or cash equivalent $16,600.00 General

Research Studies & Clinical Trials

Study Name Company Amount Records
A Randomized, Double Blind, Placebo-controlled, Dose Ranging, Parallel-group study of the Efficacy and Safety of Plecanatide in Chinldren 6 to 18 Years of Age with Irritable Bowel Syndrome with Constipation IBS-C Bausch Health US, LLC $52,800 1

About Dr. Sam Teichman, MD

Dr. Sam Teichman, MD is a Cardiovascular Disease healthcare provider based in Oakland, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/01/2014. The National Provider Identifier (NPI) number assigned to this provider is 1679998504.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sam Teichman, MD has received a total of $620,961 in payments from pharmaceutical and medical device companies, with $33,400 received in 2020. These payments were reported across 43 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($559,410).

Practice Information

  • Specialty Cardiovascular Disease
  • Location Oakland, CA
  • Active Since 03/01/2014
  • Last Updated 03/01/2014
  • Taxonomy Code 207RC0000X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1679998504

Products in Payments

  • Trulance (Drug) $268,800
  • TRULANCE (Drug) $52,800
  • (815) Thiola (Drug) $22,110

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Cardiovascular Disease Doctors in Oakland